New law to stabilise SHI fund finances – Changes to AMNOG are now finalized
On Friday, 21 Oct 2022, the German House of Representatives has now finalized the law on the financial stabilization of statutory health
Category: AMNOG law
Lung cancer drug taken off German market because of no additional benefit rating
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
Federal Cabinet has agreed new law to stabilise SHI finances
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
AOK raises further critique on draft law to stabilise SHI finances
Recently, I wrote about the planned reforms that the German Health Minister, Karl Lauterbach, wants to introduce with the act to stabilise
German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
The German Health Minister reveals his plans for the next months
Welcome to another post on possible changes and the plans of the German Health Minister for the healthcare system in the next
Prof. Dr. Karl Lauterbach is the new German health minister
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot
New government coalition plans AMNOG, pricing and other reforms
The new government in Germany is formed as a coalition of the three parties, SDP, FDP and the Green Party. At the
Why did the G-BA assess Trimbow now?
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that
When can an off-label drug be the appropriate comparator therapy?
This question was discussed at the recent G-BA meeting on 2 September 2021. Previously, the G-BA had decided on the following procedural